Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.

Research output: Contribution to journalArticle

Authors

Colleges, School and Institutes

Abstract

NTBC has revolutionized the management of tyrosinaemia type I, although animal experiments have shown that long-term administration may produce corneal opacities analogous to those in tyrosinaemia type II. We have assessed the prevalence of ocular side-effects in 11 tyrosinaemia type I patients on NTBC attending the Birmingham Children's Hospital. Despite high plasma tyrosine concentrations in some patients, they did not experience symptoms or signs of ocular toxicity.

Details

Original languageEnglish
Pages (from-to)13-6
Number of pages4
JournalJournal of Inherited Metabolic Disease
Volume26
Issue number1
Publication statusPublished - 1 Jan 2003